Latest Healthcare News

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

Imricor Medical Systems has secured Charité University Hospital in Berlin as the second global site for its VISABL-VT clinical trial, marking a significant milestone in real-time MRI-guided cardiac ablation technology.

4DMedical secures Cleveland Clinic as the third major US academic medical centre to adopt its CT – VQ™ respiratory imaging technology, marking rapid commercial traction post-FDA clearance.

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.

PeopleIN Limited has announced the sale of its Health and Community brands to Healthcare Australia for $20.25 million, unlocking capital to fuel growth in infrastructure, defence, and agriculture sectors.

PeopleIN Limited has sold its health and aged care staffing arms for $20.25 million, aiming to eliminate net debt and accelerate growth in defence, engineering, and trades sectors.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

Arena REIT reports a $61 million uplift in portfolio valuation for H1 FY2026, driven by strong investor interest in early learning centres and a tightening yield environment. The company reaffirms its FY2026 distribution guidance, signaling confidence in its growth trajectory.

Arena REIT has declared a quarterly distribution of 4.8125 cents per security, aligning with its FY26 guidance, while offering a discounted Dividend Reinvestment Plan to investors.